The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...
DUBLIN, Dec. 9, 2019 /PRNewswire/ -- The "Global Spinal Cord Stimulation (SCS) Market: Size, Trends & Forecasts (2019-2023)" report has been added to ResearchAndMarkets.com's offering. Global Spinal ...
Please provide your email address to receive an email when new articles are posted on . Abbott has announced the FDA expanded the indication of its BurstDR spinal cord stimulation devices for treating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback